Brain Repair: Gatekeeping astrocyte identity
New findings cast doubt on whether suppressing the RNA-binding protein PTBP1 can force astrocytes to become dopaminergic neurons.
- Centre for Developmental Neurobiology, King's College London, United Kingdom
- The Francis Crick Institute, United Kingdom
- University Medical Center of the Johannes Gutenberg University, Germany
As a cell acquires its final identity, it usually closes the door on the other cellular fates it could have adopted. Valiant guardian mechanisms ensure that this gate remains shut, even as a plethora of signals threaten to crack it open once more. These processes are particularly crucial for cells from highly related lineages – such as astrocytes and neurons, two types of brain cells that derive from the same progenitor cells.
In the past 15 years, work has shown that astrocytes, which belong to a class of non-neuronal cells that support and fine-tune the activity of nerve cells, can be converted into neurons if they are forced to express neurogenic transcription factors (Götz and Bocchi, 2021). In some brain regions such as the mouse striatum, injury can even re-activate a neurogenic programme which is otherwise suppressed (Magnusson et al., 2014). This raises the intriguing possibility that specific mechanisms help to safeguard the identity of astrocytes; these processes could also be harnessed to awaken neurogenic potential in astrocytes and help repair neural damage.
A top-selling candidate for gatekeeping the astrocyte-to-neuron conversion is the RNA-binding PTBP1 which, in vitro, inhibits neuronal fate by ensuring that a master repressor of neuronal genes remains active (Makeyev et al., 2007). The discovery of these regulatory interactions suggested that simply downregulating PTBP1 could release the brake on a neurogenic programme in non-neuronal cells (Xue et al., 2013; Figure 1A). In fact, two recent bodies of work suggest that when PTBP1 is knocked down, mouse astrocytes can turn into dopaminergic neurons with remarkable efficiency (Qian et al., 2020, Zhou et al., 2020). This class of nerve cells degenerates in Parkinson’s disease, and both studies reported a drastic amelioration of motor deficits in a mouse model of this condition, with enormous implications for new brain therapies. Now, in eLife, Mingtao Li and colleagues at Sun Yat-sen University – including Weizhao Chen as first author – report results that question these findings (Chen et al., 2022).
Figure 1
Deactivating PTBP1 in astrocytes fails to convert the cells into neurons.
(A) The hypothesis tested by Chen et al. is that the protein PTBP1 stops astrocytes (pale pink) from becoming neurons (grey). (B) Adeno-associated viruses (green) can deliver the genetic information necessary to deactivate PTBP1 in astrocytes which have been genetically tagged (red). This potentially allows the cells to be converted into dopaminergic neurons which still carry the tag (red) reflecting that they have originated from astrocytes, as well as the viral label (green). (C) Chen et al. used a mouse model in which astrocyte origin could be traced to investigate whether knocking down PTBP1 using adeno-associated viruses may lead to the cells becoming dopaminergic neurons (DA carrying the red tag); this turned out not to be the case (red cross). Instead, dopaminergic neurons carrying the viral signal (green-only cells) were identified, which did not originate from astrocytes. (D) Similar experiments were conducted in a mouse model of Parkinson’s disease. In this instance, a toxin was introduced to kill endogenous dopaminergic neurons and render resting astrocytes reactive; in this injury-triggered state, astrocytes exhibit features associated with stem cells. Deactivating PTBP1 in reactive astrocytes again failed to turn them into neurons, and the mice still exhibited motor deficits.
The team focused on whether the seemingly converted dopaminergic cells truly derived from astrocytes, using a transgenic mouse line that faithfully reports the origin of astrocytes. PTBP1 was successfully knocked down in astrocytes by using adeno-associated viruses, viral vectors that contain the information necessary to suppress the protein only in astrocytes (Figure 1B).
Dopaminergic neurons carrying the viral label were identified, but to the team’s surprise, none of these were positive for the genetic tag that marked astrocyte origin (Figure 1C). This data strongly suggests that these neurons have not emerged from converted astrocytes, but that instead the viral vectors had lost their original specificity. This adds to recent, baffling observations, which highlighted that adeno-associated viruses designed to activate the expression of neuronal conversion factors only in astrocytes, fail to attain the required specificity (Wang et al., 2021).
Chen et al. then checked whether the manipulation could be successful if done on a type of astrocyte that may be more prone to changing its identity. These ‘reactive’ astrocytes emerge in damaged tissues, where they start to display traits present in neural stem cells (Sirko et al., 2013). A toxin was used to kill dopaminergic neurons as PTBP1 was suppressed in reactive astrocytes, yet even this scenario failed to turn the cells into neurons (Figure 1D). Conducting this manipulation in a mouse model of Parkinson’s disease also did not lead to improvements in the animals’ motor deficits. How this negative finding can be reconciled with earlier studies showing that these symptoms were corrected upon PTBP1 deactivation will require further clarification.
Taken together, the work by Chen et al. strongly argues against PTBP1 being the sole gatekeeper between astrocyte and neuronal fates, while also stressing the importance of rigorous genetic lineage tracing when conducting in vivo reprogramming. Still, given the powerful control that PTBP1 exerts on the molecular switch that represses neuronal genes, it would be premature to fully move away from studying the impact of this protein on astrocyte identity and function.
References
-
Neuronal replacement: Concepts, achievements, and call for cautionCurrent Opinion in Neurobiology 69:185–192.https://doi.org/10.1016/j.conb.2021.03.014
Article and author information
Author details
Benedikt Berninger
Publication history
Copyright
© 2022, Cooper and Berninger
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 843
- views
-
- 170
- downloads
-
- 5
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Brain Repair: Gatekeeping astrocyte identity
eLife 11:e80232.
https://doi.org/10.7554/eLife.80232
Further reading
-
- Neuroscience
Dense core vesicles (DCVs) transport and release various neuropeptides and neurotrophins that control diverse brain functions, but the DCV secretory pathway remains poorly understood. Here, we tested a prediction emerging from invertebrate studies about the crucial role of the intracellular trafficking GTPase Rab10, by assessing DCV exocytosis at single-cell resolution upon acute Rab10 depletion in mature mouse hippocampal neurons, to circumvent potential confounding effects of Rab10’s established role in neurite outgrowth. We observed a significant inhibition of DCV exocytosis in Rab10-depleted neurons, whereas synaptic vesicle exocytosis was unaffected. However, rather than a direct involvement in DCV trafficking, this effect was attributed to two ER-dependent processes, ER-regulated intracellular Ca2+ dynamics, and protein synthesis. Gene Ontology analysis of differentially expressed proteins upon Rab10 depletion identified substantial alterations in synaptic and ER/ribosomal proteins, including the Ca2+ pump SERCA2. In addition, ER morphology and dynamics were altered, ER Ca2+ levels were depleted, and Ca2+ homeostasis was impaired in Rab10-depleted neurons. However, Ca2+ entry using a Ca2+ ionophore still triggered less DCV exocytosis. Instead, leucine supplementation, which enhances protein synthesis, largely rescued DCV exocytosis deficiency. We conclude that Rab10 is required for neuropeptide release by maintaining Ca2+ dynamics and regulating protein synthesis. Furthermore, DCV exocytosis appeared more dependent on (acute) protein synthesis than synaptic vesicle exocytosis.
-
- Neuroscience
By influencing calcium homeostasis, local protein synthesis and the endoplasmic reticulum, a small protein called Rab10 emerges as a crucial cytoplasmic regulator of neuropeptide secretion.
